ALMDT Median Technologies SA
Median Technologies SA develops and markets software solutions and services for the use of medical images for the diagnosis and monitoring of patients with cancer in Europe, North America, and Asia. The company offers iCRO, an imaging service for oncology clinical trials; and eyonis, an end-to-end CADe/CADx software as medical devices. The company was founded in 2002 and is based in Valbonne, France.…
Industry Peers
Medical DevicesKey Statistics
About Median Technologies (EPA: ALMDT)
›
Median Technologies (EPA: ALMDT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 200 employees.
The shares were at 4.300 EUR on 19 November 2026, up 52.8% over 52 weeks. Its 52-week range is 2.750 EUR to 7.270 EUR: the price is 40.9% below the high and 56.4% above the low.
Its market capitalisation is 207.75M EUR.
Median Technologies reports return on equity of 96.9%, an operating margin of -101.5% and revenue up 3.5% year over year.
It holds more cash than debt, a net cash position of 34.89M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 11.97 EUR is 178.3% above the current price.